Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · Real-Time Price · USD
0.981
-0.005 (-0.49%)
At close: Dec 20, 2024, 4:00 PM
0.980
-0.001 (-0.11%)
After-hours: Dec 20, 2024, 4:40 PM EST
Achilles Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ACHL stock have an average target of 4.00, with a low estimate of 2.00 and a high estimate of 6.00. The average target predicts an increase of 307.71% from the current stock price of 0.98.
Analyst Consensus: Buy
* Price targets were last updated on Apr 5, 2024.
Analyst Ratings
The average analyst rating for ACHL stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +103.85% | Apr 5, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $6 | Strong Buy | Maintains | $11 → $6 | +511.56% | Apr 5, 2024 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $0.5 | Strong Buy → Sell | Downgrades | $7 → $0.5 | -49.04% | Dec 14, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +1,021.19% | Aug 7, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +1,021.19% | May 11, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.60
from -1.74
EPS Next Year
-0.89
from -1.60
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | |||
| Avg | n/a | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.65 | -0.91 | -2.88 | ||
| Avg | -1.60 | -0.89 | -2.79 | ||
| Low | -1.54 | -0.85 | -2.69 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.